Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has presented results from a Phase III pivotal study in which Vyvanse has demonstrated significant improvements in attention deficit hyperactivity disorder symptoms in adults and met all safety and efficacy endpoints.
Subscribe to our email newsletter
This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with Vyvanse at all doses studied (30mg, 50mg, 70mg) provided a significant reduction in attention deficit hyperactivity disorder rating scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period.
At endpoint, Vyvanse demonstrated a significant improvement in ADHD symptoms, based on a 43% reduction in ADHD-RS scores. This is said to be the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.
Lenard Adler, lead researcher in this study, said: “This study demonstrated that Vyvanse significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity.”